Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

American Academy of Neurology Annual Meeting
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
“Human Medicines” page
Immunology 2015
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Webinar: "Seeking Best Practices in Classifier Construction and Testing"
The Brain as a Target of Inflammatory Processes
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Rituximab does not reset defective early B cell tolerance checkpoints.
Episode 29 with Dr. Monica Carson on MS research funding
Dimethylfumarate Impairs Neutrophil Functions.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Episode 32 with Dr. David Holtzman on the connection between MS and Alzheimer 's disease
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development

Pages